ERBB2 and breast carcinoma: The MONARCH E trial, a phase III open-label study, evaluated abemaciclib combined with adjuvant endocrine therapy versus endocrine therapy alone in 5,637 high-risk patients with HR+/HER2-, lymph node-positive early breast cancer.